Investigational drug · Phase 3
KSI-101
Also called: tabirafusp
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Macular Edema Secondary to Inflammation.
Phase 3Last checked: Nov 19, 2026Latest source record: May 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "KSI-101"
First trial start
2025
Jul 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KSI-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Macular Edema Secondary to Inflammation
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "KSI-101" as an intervention, largest first.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKPivotal-lookingRecruiting
Kodiak Sciences IncIndustry
NCT06990399 · 600 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: KSI-101 · For: Macular Edema Secondary to Inflammation
Sites: Phoenix, Arizona; Scottsdale, Arizona; Bakersfield, California · 56 sites in all
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLEPivotal-lookingRecruiting
Kodiak Sciences IncIndustry
NCT06996080 · 300 participants (planned) · Start Jul 16, 2025 · Primary completion Feb 2027
Drug: KSI-101 · For: Macular Edema Secondary to Inflammation
Sites: Phoenix, Arizona; Scottsdale, Arizona; Bakersfield, California · 56 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.